Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CYTK – Cytokinetics, Incorporated

Cytokinetics, Incorporated
CYTK
$36.69
Name : Cytokinetics, Incorporated
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $4,381,776,384.00
EPSttm : -5.29
finviz dynamic chart for CYTK
Cytokinetics, Incorporated
$36.69
2.52%
$0.95

Float Short %

13.64

Margin Of Safety %

Put/Call OI Ratio

0.18

EPS Next Q Diff

-0.02

EPS Last/This Y

-0.27

EPS This/Next Y

0.13

Price

36.69

Target Price

71.11

Analyst Recom

1.41

Performance Q

-14.52

Relative Volume

0.63

Beta

0.65

Ticker: CYTK




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04CYTK34.660.170.01101207
2025-07-07CYTK33.370.170.36101551
2025-07-08CYTK34.250.170.26100917
2025-07-09CYTK36.630.170.08100945
2025-07-10CYTK36.570.170.08102046
2025-07-11CYTK370.170.05102253
2025-07-14CYTK38.570.170.10102592
2025-07-15CYTK38.030.170.60103214
2025-07-16CYTK38.710.170.64103525
2025-07-17CYTK38.880.170.37104295
2025-07-18CYTK37.220.170.50103950
2025-07-21CYTK36.970.180.6578358
2025-07-22CYTK37.790.180.0778589
2025-07-23CYTK37.930.180.7278587
2025-07-24CYTK37.430.180.8877227
2025-07-25CYTK37.170.180.5077815
2025-07-28CYTK36.620.188.8677902
2025-07-29CYTK35.90.180.1578012
2025-07-30CYTK36.180.180.0378026
2025-07-31CYTK37.640.180.2378197
2025-08-01CYTK36.670.180.1378654
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04CYTK34.66-3.2-154.5-5.48
2025-07-07CYTK33.36-3.2-122.3-5.48
2025-07-08CYTK34.25-3.2-167.1-5.48
2025-07-09CYTK36.62-3.2-196.7-5.48
2025-07-10CYTK36.59-3.2-147.8-5.48
2025-07-11CYTK37.01-3.2-155.6-5.48
2025-07-14CYTK38.60-3.2-178.2-5.48
2025-07-15CYTK38.01-3.2-138.1-5.48
2025-07-16CYTK38.70-3.2-161.0-5.48
2025-07-17CYTK38.89-3.2-152.2-5.48
2025-07-18CYTK37.24-3.2-119.0-5.48
2025-07-21CYTK36.97-3.2-143.5-5.48
2025-07-22CYTK37.68-3.2-162.0-5.48
2025-07-23CYTK37.93-3.2-152.6-5.48
2025-07-24CYTK37.31-3.2-137.0-5.48
2025-07-25CYTK37.18-3.2-145.9-5.48
2025-07-28CYTK36.66-3.2-138.7-5.48
2025-07-29CYTK35.90-3.2-134.5-5.48
2025-07-30CYTK36.18-3.2-153.8-5.48
2025-07-31CYTK37.64-4.1-176.4-5.53
2025-08-01CYTK36.69-4.1-130.7-5.53
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04CYTK-9.216.8712.00
2025-07-07CYTK-9.216.8711.99
2025-07-08CYTK-9.426.8711.99
2025-07-09CYTK-9.426.8711.99
2025-07-10CYTK-9.426.8711.99
2025-07-11CYTK-9.366.8712.86
2025-07-14CYTK-9.366.7312.86
2025-07-15CYTK-9.526.7312.86
2025-07-16CYTK-9.526.7312.86
2025-07-17CYTK-9.526.7312.86
2025-07-18CYTK-9.526.7312.86
2025-07-21CYTK-9.526.6812.86
2025-07-22CYTK-9.496.6812.86
2025-07-23CYTK-9.566.6812.86
2025-07-24CYTK-9.566.6812.86
2025-07-25CYTK-9.566.6813.64
2025-07-28CYTK-9.566.6113.64
2025-07-29CYTK-9.566.6113.64
2025-07-30CYTK-9.566.6113.64
2025-07-31CYTK-9.716.6113.64
2025-08-01CYTK-9.716.6113.64
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-1.39

Avg. EPS Est. Current Quarter

-1.35

Avg. EPS Est. Next Quarter

-1.41

Insider Transactions

-9.71

Institutional Transactions

6.61

Beta

0.65

Average Sales Estimate Current Quarter

1

Average Sales Estimate Next Quarter

5

Fair Value

Quality Score

8

Growth Score

40

Sentiment Score

10

Actual DrawDown %

66.7

Max Drawdown 5-Year %

-72.4

Target Price

71.11

P/E

Forward P/E

PEG

P/S

227.98

P/B

P/Free Cash Flow

EPS

-5.31

Average EPS Est. Cur. Y​

-5.53

EPS Next Y. (Est.)

-5.41

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-3201.47

Relative Volume

0.63

Return on Equity vs Sector %

207.2

Return on Equity vs Industry %

225.9

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.05

EBIT Estimation

-130.7
Cytokinetics, Incorporated
Sector: Healthcare
Industry: Biotechnology
Employees: 498
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
stock quote shares CYTK – Cytokinetics, Incorporated Stock Price stock today
news today CYTK – Cytokinetics, Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch CYTK – Cytokinetics, Incorporated yahoo finance google finance
stock history CYTK – Cytokinetics, Incorporated invest stock market
stock prices CYTK premarket after hours
ticker CYTK fair value insiders trading